1. Background {#sec1-cancers-12-00918}
=============

Gallbladder cancer (GBC) is a rare and highly lethal neoplasm of the biliary tract. GBC demonstrates marked geographic, age-, gender-, and ethnicity-related differences in incidence, implying (epi)genetics or environmental factors may play an important role in the development of GBC \[[@B1-cancers-12-00918],[@B2-cancers-12-00918],[@B3-cancers-12-00918],[@B4-cancers-12-00918],[@B5-cancers-12-00918],[@B6-cancers-12-00918]\]. Other possible risk factors include cholelithiasis, obesity, gallbladder polyps, chronic infections, and an abnormal pancreaticobiliary duct junction \[[@B1-cancers-12-00918],[@B7-cancers-12-00918],[@B8-cancers-12-00918]\].

Treatment of GBC remains challenging. Diagnosis---unless incidentally after cholecystectomy for benign gallbladder disease---is often made in an advanced stage and survival is extremely poor due to the limited efficacy of systemic therapy options \[[@B3-cancers-12-00918]\]. The only treatment with curative intent is surgical resection. However, due to late detection and a tendency towards invasive local growth, only 10% to 25% of tumors are candidates for potential curative intent surgery at presentation \[[@B9-cancers-12-00918],[@B10-cancers-12-00918]\]. Even after resection 5-year survival rates are poor, ranging from 12% to 40% in non-incidental tumors \[[@B3-cancers-12-00918],[@B11-cancers-12-00918],[@B12-cancers-12-00918]\]. Long-term survival is only observed in patients with early (T1/T2) GBC, which is mainly diagnosed incidentally. However, even for these patients, additional radical surgery with resection of the gallbladder bed and lymph node dissection of the hepatoduodenal ligament is recommended because it is thought to considerably increase survival \[[@B13-cancers-12-00918],[@B14-cancers-12-00918]\].

The limited benefit of systemic therapy in GBC has been shown in prospective trials; in 2010, the ABC-02 trial reported a median overall survival (OS) of 11.7 months vs. 8.1 months in unresectable biliary tract cancer treated with gemcitabine and cisplatin versus gemcitabine alone \[[@B15-cancers-12-00918]\]. This has since been adopted as the standard regimen in the treatment of unresectable GBC. Although several randomized clinical trials have investigated the value of adjuvant chemotherapy for biliary tract cancers, none have found a survival benefit in the intention-to-treat analysis and no adequately powered subgroup analyses for GBC have been conducted \[[@B16-cancers-12-00918],[@B17-cancers-12-00918]\].

Guidelines for the treatment of localized GBC are mainly based on retrospective evidence and expert opinion due to the minimal availability of randomized evidence. Previous studies investigating GBC have typically been conducted in high-volume, non-Western centers and included patients with various biliary tract cancers \[[@B15-cancers-12-00918],[@B18-cancers-12-00918],[@B19-cancers-12-00918]\]. Due to presumed different etiologies, results in GBC may differ from those in other biliary tract tumors \[[@B20-cancers-12-00918]\].

Our objective was to investigate trends in treatment, establish prognostic factors associated with survival and identify opportunities for improvement in treatment stratified for disease stage.

2. Methods {#sec2-cancers-12-00918}
==========

This is a cohort study using data from the nationwide population-based Netherlands Cancer Registry (NCR), containing information on all newly diagnosed malignancies. The NCR receives notifications from the automated pathological archive (PALGA), the nation-wide network and registry of histo- and cytopathology in the Netherlands, and is supplemented by alerts from the National Archive of Hospital Discharge Diagnosis \[[@B21-cancers-12-00918]\]. Completeness of the registry is estimated to be at least 95% \[[@B22-cancers-12-00918]\]. Since all data was anonymized a waiver for ethical approval was provided. The STROBE guidelines for reporting of observational studies have been followed \[[@B23-cancers-12-00918]\]. This study was approved by the NCR ethical review board and a waiver for ethical approval was provided by the Medical Ethics Review Committee of the region Arnhem-Nijmegen (CMO A-N, nr. 2017-3912) on 27/12/2017. The study was conducted according to the Declaration of Helsinki. Anonymized patient level data are available upon request from the Netherlands Cancer Registry. The statistical code is available upon request from the corresponding author.

2.1. Patient Selection and Variable Definitions {#sec2dot1-cancers-12-00918}
-----------------------------------------------

Clinicopathological data on all adult patients diagnosed between 2005 and 2016 with invasive gallbladder neoplasms were extracted. The following variables were provided: age, gender, year of diagnosis, socioeconomic status (social deprivation scores based on a mean number of 4000 inhabitants per 4-digit postal codes), histopathological or clinical diagnosis, tumor histology (based on the ICD-O3 classification, morphological codes are provided in [Appendix A](#app1-cancers-12-00918){ref-type="app"}), clinical and pathological TNM stage (AJCC staging system, version 6 for patients diagnosed from 2005 to 2009 and version 7 from 2010 to 2016 \[[@B24-cancers-12-00918],[@B25-cancers-12-00918]\]), presence and location of metastatic disease, occurrence of syn- or metachronous primary tumors, type of resection performed, resection margin (R0: microscopically free of tumor, R1 microscopically positive for tumor, R2: macroscopically positive for tumor), systemic therapy (yes/no), radiation therapy (yes/no), and duration of follow-up in days from date of diagnosis. Missing data occurred in four out of nine baseline variables (2% to 29%) and was not imputed because it was determined not to be missing at random.

Primary radical/extended cholecystectomy was defined as cholecystectomy with en-bloc excision of the gallbladder bed and dissection of the hepatoduodenal lymph nodes as the first surgery received by the patient. Re-resection was defined as any surgery for GBC after initial cholecystectomy alone within 180 days of diagnosis. Radicality was classified into R0 (resection margin microscopically free of tumor) and R1/2 (resection margin micro- or macroscopically positive). Supportive therapy included endoscopic procedures, biliary drainage and metastasectomy. Ninety-day mortality was defined as death within 90 days of diagnosis. Chemo- and radiotherapy were defined as administration of at least one dose. Information regarding type of systemic therapy received was not available. Follow-up data on vital status (complete until February 2018) were provided by linkage to the automated Municipal Personal Records Database.

2.2. Quality Control and Completeness of Data Assessment {#sec2dot2-cancers-12-00918}
--------------------------------------------------------

Accuracy of diagnosis and completeness of histopathological assessment was assessed by comparing data from the resected patients provided by the NCR with data extracted from the medical records available from four academic centers in the Netherlands: Radboudumc, Amsterdam University Medical Center (location AMC), Erasmus MC and Leiden University Medical Center.

2.3. Statistical Analysis {#sec2dot3-cancers-12-00918}
-------------------------

Characteristics were described using counts and percentages for continuous variables and means and ranges for continuous variables. χ-square testing or Fisher's exact test, where appropriate, were used to assess differences in patient characteristics. Incidence rates were calculated per 100,000 person years and age-standardized using the European standard population. Trends in incidence were assessed by calculating the estimated annual percentage change (EAPC).

Patients were grouped according to T-stage (T1/T2 vs. T3/T4), N-stage (N0 vs. N1/N2) and resection margin (R0 vs. R1/R2 vs. Rx). For survival analyses, patients were categorized as resected, non-metastatic non-resected (i.e., inoperable patients due to comorbidities and/or locally advanced disease) or metastatic at diagnosis. To assess trends in treatment over time, patients were grouped according to period of diagnosis (Period 1; 2005--2009 and Period 2; 2010--2016; these periods coincide with the introduction of gemcitabine-cisplatin chemotherapy as standard of care for unresected BTC). A subgroup analysis in patients with early (T1b/T2) disease was conducted to assess trends in surgical treatment. Kaplan-Meier curves were used to calculate median OS. OS was defined as time in days from date of diagnosis until date of death from any cause or the date of last follow-up (February 2018). Patients alive at the last date of follow-up were censored. Cox regression analysis was used to calculate hazard ratios for potential prognostic factors. Covariates were selected based on literature and entered in the multivariable model when statistically relevant (*p* \< 0.1) on univariable analysis. *p*-values \< 0.05 were considered statistically significant. All tests of significance were two-tailed. Statistical analyses were conducted using the SPSS 24.0 statistical package (SPSS, Inc., Chicago, IL).

3. Results {#sec3-cancers-12-00918}
==========

3.1. Incidence and Patient and Tumor Characteristics {#sec3dot1-cancers-12-00918}
----------------------------------------------------

Patient and tumor characteristics are shown in [Table 1](#cancers-12-00918-t001){ref-type="table"}. Between 2005 and 2016, 1834 patients were diagnosed with GBC in the Netherlands ([Figure 1](#cancers-12-00918-f001){ref-type="fig"}). Forty-nine percent of patients had metastatic disease at diagnosis (43% from 2005 to 2009 and 53% from 2010 to 2016, *p* \< 0.001). The incidence of GBC did not change significantly (EAPC---0.7%, *p* = 0.32) over time ([Appendix B](#app2-cancers-12-00918){ref-type="app"}). Median age at diagnosis was 71 (IQR 64--80) years. Eighty percent of patients had histopathological confirmation of diagnosis.

3.2. Treatment {#sec3dot2-cancers-12-00918}
--------------

Time trends in treatment in resected, non-resected non-metastatic, and metastatic GBC are shown in [Figure 2](#cancers-12-00918-f002){ref-type="fig"}. Among all patients with non-metastatic disease, primary resection rates increased; 64.7% in 2005 to 2009 to 74.8% in 2010 to 2016 (*p* = 0.001). More extensive tumors (T3--T4) were resected between 2010 and 2016 compared to 2009 to 2015 (from 25.1% to 33.1%, *p* \< 0.001). In resected, non-metastatic patients, 90-day mortality decreased from 12.0% to 5.6% (*p* = 0.003) and the percentage of patients receiving R0 resection did not change significantly (from 70.3% to 74.7%, *p* = 0.294). The number of patients receiving an extended cholecystectomy (with/without hepatoduodenal lymphadenectomy) opposed to simple cholecystectomy in early (T1b--T2) GBC increased significantly, from 19% to 33% (*p* \< 0.001). In the subgroup analysis conducted in patients with early GBC, 90-day mortality and the R0 resection rate did not change over time. Adjuvant chemotherapy was only administered to 12/661 (1.8%) patients.

Use of palliative chemotherapy did not increase in patients with unresected, non-metastatic GBC (15% vs. 15%, [Figure 2](#cancers-12-00918-f002){ref-type="fig"}). The use of palliative chemotherapy in metastatic GBC increased from 11% to 29% (*p* \< 0.001).

3.3. Survival {#sec3dot3-cancers-12-00918}
-------------

Median OS of the entire cohort was 5.5 months (95% CI 5.0--6.0) and increased from 4.8 months (95% CI 4.2--5.4) in 2005 to 2009 to 6.1 months (95% CI 5.4--6.8) in 2010 to 2016 (*p* = 0.012) ([Figure 3](#cancers-12-00918-f003){ref-type="fig"}A). Median OS differed significantly between resected and non-metastatic non-resected/metastatic disease: 23.7 (95% CI 19.6--27.8), 3.6 (95% CI 3.1--4.6) and 2.7 (95% CI 2.6--3.2) months, respectively (*p* \< 0.001, [Figure 3](#cancers-12-00918-f003){ref-type="fig"}B). Resected patients showed improved median OS over time; from 19.4 to 26.8 months (*p* = 0.038, [Appendix C](#app3-cancers-12-00918){ref-type="app"}). Median OS in metastatic patients increased from 2.3 to 3.4 months (*p* \< 0.001, [Appendix C](#app3-cancers-12-00918){ref-type="app"}). In non-resected patients survival did not change significantly over time.

3.4. Therapy and Survival {#sec3dot4-cancers-12-00918}
-------------------------

Survival in patient groups with resected, non-metastatic non-resected and metastatic GBC is shown in [Table 2](#cancers-12-00918-t002){ref-type="table"}. The survival benefit of adjuvant chemotherapy could not be assessed since only 12 out of 661 patients received some form of adjuvant therapy. Radical surgery (either primary radical cholecystectomy or re-resection) in early GBC was associated with a significantly higher median OS compared to simple cholecystectomy, from 18.4 to 76.7 months (*p* \< 0.001). Palliative chemotherapy in non-resected non-metastatic and metastatic disease was associated with superior survival; from 3.5 to 7.7 (*p* = 0.011) and 2.1 versus 7.3 (*p* \< 0.001) months, respectively.

3.5. Prognostic Factors for Survival {#sec3dot5-cancers-12-00918}
------------------------------------

Poor prognostic factors were increasing age, poor tumor differentiation, higher T-stage, presence of lymph node metastases and (in resected patients) non-radical resection [Table 3](#cancers-12-00918-t003){ref-type="table"}.

Palliative surgery and chemotherapy were associated with a better prognosis in metastatic disease (HR 0.43 and 0.47 respectively, *p* \< 0.001).

3.6. Quality Control {#sec3dot6-cancers-12-00918}
--------------------

In total, 108 patients (16% of resected patients) underwent a resection in one of the four academic hospitals. One patient (0.9%) turned out to have cholecystitis and was incorrectly registered by the NCR as having GBC.

4. Discussion {#sec4-cancers-12-00918}
=============

Between 2000 and 2016, no (clinically) significant changes in incidence and survival of GBC were seen. Although radical surgery in early GBC and palliative chemotherapy in unresectable and metastatic GBC significantly improved survival, these treatment modalities were only used in 33% (radical surgery) and 25% (palliative chemotherapy) of patients.

The survival rates as demonstrated in this study are comparable to those from a previously published Western cohorts \[[@B26-cancers-12-00918],[@B27-cancers-12-00918]\], but inferior to survival rates from non-Western centers: three-year survival was 73% for stage I (53% in stage II) in our study compared to 100% (80% in stage II) in a recently conducted Korean study including 142 patients \[[@B28-cancers-12-00918]\]. These differences are possibly attributable to selection bias in high-volume expert centers in non-Western countries, different tumor biology or differences in the administration of adjuvant chemotherapy, which has not been standard practice in the Netherlands \[[@B29-cancers-12-00918]\].

In a subgroup analysis, improved survival over time was only seen in resected and metastatic GBC. The improved outcome of resected patients is likely the result of multiple factors. Although primary resection rates remained stable, larger tumors (T3/T4) were increasingly resected and 90-day mortality decreased significantly over time, suggesting an improvement in operative techniques or postoperative care. A sharp increase in re-resection rates for early GBC was seen after 2010, coinciding with a change in national guidelines advocating for the use of additional gallbladder bed resection and regional lymphadenectomy in early (pT1b/T2) GBC, which is associated with significantly improved outcomes \[[@B14-cancers-12-00918],[@B30-cancers-12-00918],[@B31-cancers-12-00918],[@B32-cancers-12-00918],[@B33-cancers-12-00918]\]. Our results support this notion; patients with early GBC who received radical surgery had a median OS that was over three times larger (76.7 vs. 18.4 months) than the survival of patients who did not undergo radical resection.

Unfortunately, our results suggest substantial undertreatment; even during the last study period only 33% of patients with early-stage GBC received the recommended radical surgery in addition to cholecystectomy alone. Most likely, the majority of the early GBC patients are diagnosed incidentally after cholecystectomy for suspected benign gallbladder disease by a general gastrointestinal surgeon in a community hospital. We hypothesize that many clinicians still perceive advanced GBC as an untreatable disease and thus may be reluctant to refer patients to a specialized hepatobiliary center for additional surgery or chemotherapy. We believe that multidisciplinary, specialized care, and better adherence to (inter-)national guidelines may improve prognosis of GBC patients.

Previous studies show conflicting results on the value of adjuvant chemotherapy. Most evidence is based on small, retrospective series and only one recently published phase-3 trial showed a survival benefit in the per-protocol analysis alone \[[@B17-cancers-12-00918]\]. Currently, recruiting large, prospective trials may show more positive results \[[@B34-cancers-12-00918]\]. Unfortunately, the effect of adjuvant therapy after resection could not be assessed as adjuvant therapy is currently not standard of care in the Netherlands and was only administered to a small number of cases (most likely in a clinical trial setting).

In 2010, the ABC-02 trial demonstrated a survival benefit of gemcitabine and cisplatin in metastatic biliary tract cancer \[[@B15-cancers-12-00918]\], resulting in an update of the national guidelines and palliative chemotherapy becoming standard of care. Although a subsequent rise from 15% to 25% in the use of palliative chemotherapy was seen after 2010, it was still infrequently administered. Since (subsidized) healthcare insurance is mandatory for all inhabitants of the Netherlands and travel distance to healthcare is generally short, the most likely explanation for this poor delivery rate is nihilism regarding the efficacy of chemotherapy. Evidently, chemotherapy in non-resectable GBC warrants further attention since the increase in use of palliative chemotherapy is a likely cause for the (minor) improvement in median OS in metastatic GBC.

The major limitation of this study pertains to the nature of registration data; because of the retrospective nature of this study, selection bias is present. Caution should be exercised when interpreting results, especially when analyzing treatment strategies and associated differences in survival. Additionally, possible incompleteness of data in the earlier years and changes in registry guidelines resulted in missing data on prognostic factors such as T- and N-stage (16%) in unresected patients and tumor grade (29%) in resected patients.

Second, distinguishing GBC from perihilar cholangiocarcinoma (proximal extrahepatic cholangiocarcinoma, pCC) is challenging in locally advanced disease \[[@B35-cancers-12-00918]\]. Diagnosis in unresected patients was based on imaging only and histopathological confirmation was available in 76% of patients. However, recent research highlights the importance of this distinction, as GBC and pCC show different molecular landscapes and consequently might benefit from different treatment options \[[@B20-cancers-12-00918],[@B36-cancers-12-00918],[@B37-cancers-12-00918]\]. The results from this study reflect current clinical practice until more reliable diagnostic methods to differentiate between GBC and pCC become available.

A unique strength of this study is the nation-wide, population based design resulting in an accurate representation of treatment and survival patterns of gallbladder cancer in daily clinical practice in a low incidence population. In addition, we were able to perform a quality control and demonstrated that the accuracy of the registration data is very high, since only 1 out of 108 patients received an incorrect diagnosis.

5. Conclusions {#sec5-cancers-12-00918}
==============

In conclusion, survival of GBC is poor and minimal improvement has been made in the past decade in the Netherlands. Radical surgery in early GBC and palliative chemotherapy in unresectable and metastatic GBC are associated with increased OS. However, the use of these treatment modalities is still limited. A multidisciplinary approach in GBC involving radical surgery and systemic therapy may lead to improvement in the survival of GBC patients.
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ICD-03 code

Frequency

(%)

8000

Neoplasma

310

(16.6)

8001

Tumor cells

2

(0.1)

8010

Carcinoma, NOS

50

(2.7)

8012

Large cell carcinoma NOS

35

(1.9)

8013

Large cell neuroendocrine carcinoma

6

(0.3)

8020

Carcinoma, undifferentiated, NOS

5

(0.3)

8030

Giant cell and spindle cell carcinoma

2

(0.1)

8032

Spindle cell carcinoma, NOS

2

(0.1)

8033

Pseudosarcomatous carcinoma

3

(0.2)

8041

Small cell carcinoma, NOS

10

(0.5)

8046

Non-small cell carcinoma

4

(0.2)

8070

Squamous cell carcinoma, NOS

19

(1.0)

8071

Squamous cell carcinoma, keratinizing, NOS

2

(0.1)

8074

Squamous cell carcinoma, spindle cell

1

(0.1)

8140

Adenocarcinoma, NOS

1171

(62.6)

8144

Adenocarcinoma, intestinal type

21

(1.1)

8160

Cholangiocarcinoma

6

(0.3)

8163

Pancreatobiliary-type carcinoma

5

(0.3)

8210

Adenocarcinoma in adenomatous polyp

7

(0.4)

8211

Tubular adenocarcinoma

2

(0.1)

8240

Carcinoid tumor, NOS

13

(0.7)

8244

Mixed adenoneuroendocrine carcinoma

2

(0.1)

8246

Neuroendocrine carcinoma, NOS

6

(0.3)

8249

Atypical carcinoid tumor

2

(0.1)

8260

Papillary adenocarcinoma, NOS

36

(1.9)

8263

Adenocarcinoma in tubolovillous adenoma

3

(0.2)

8310

Clear cell adenocarcinoma, NOS

3

(0.2)

8312

Renal cell carcinoma, NOS

1

(0.1)

8350

Nonencapsulated sclerosing carcinoma

1

(0.1)

8480

Mucinous adenocarcinoma

31

(1.7)

8481

Mucin-producing adenocarcinoma

44

(2.4)

8490

Signet ring cell carcinoma

19

(1.0)

8500

Infiltrating duct carcinoma, NOS

2

(0.1)

8503

Intraductal papillary adenocarcinoma with invasion

4

(0.2)

8560

Adenosquamous carcinoma

26

(1.4)

8570

Adenocarcinoma with squamous metaplasia

1

(0.1)

8574

Adenocarcinoma with neuroendocrine differentiation

10

(0.5)

8575

Metaplastic carcinoma, NOS

1

(0.1)

8576

Hepatoid adenocarcinoma

1

(0.1)

8980

Carcinosarcoma, NOS

3

(0.2)
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![Trends in treatment in resected, non-resected non-metastatic, and metastatic gallbladder cancer (GBC). The grey area represents a subgroup analysis of resected patients with early (T1b/T2) gallbladder cancer. Percentages are only displayed when significant differences (*p* \< 0.05) between periods were found. Supportive treatment includes endoscopic procedures, biliary drainage and metastasectomy.](cancers-12-00918-g002){#cancers-12-00918-f002}

![(**A**): Survival according to time period. (**B**): Survival according to disease stage.](cancers-12-00918-g003){#cancers-12-00918-f003}

cancers-12-00918-t001_Table 1

###### 

Characteristics of patients with gallbladder cancer in the Netherlands (2005--2016).

  -----------------------------------------------------------------------------------------------------------------------------
  Cohort                                         Total\          Resected\       Non-resected Non-metastatic\   Metastatic\
                                                 (*n* = 1834)    (*n* = 661)     (*n* = 278)                    (*n* = 895)
  ---------------------------------------------- --------------- --------------- ------------------------------ ---------------
  Patient and tumor characteristics                                                                             

  Age                                            71.1 (22--97)   69.2 (27--97)   74.3 (32--95)                  71.2 (22--96)

  Male sex                                       545 (29.1%)     206 (31.2%)     82 (29.5%)                     250 (27.9%)

  Socioeconomic Status                                                                                          

  High                                           501 (26.8%)     183 (27.7%)     82 (29.5%)                     229 (33.4%)

  Medium                                         741 (39.6%)     253 (38.3%)     110 (39.6%)                    367 (41.0%)

  Low                                            630 (33.7%)     225 (34.0%)     86 (30.9%)                     299 (33.4%)

  Clinicopathologic T stage ^a^                                                                                 

  T1                                             526 (28.1%)     147 (22.6%)     1 (0.4%)                       54 (8.5%)

  T2                                                             303 (45.8%)     0 (0.0%)                       22 (2.5%)

  T3/T4                                          643 (34.3%)     172 (26.2%)     169 (60.8%)                    427 (47.7%)

  TX                                             496 (26.5%)     38 (5.8%)       13 (4.7%)                      302 (33.7%)

  Unknown/missing                                207 (11.1%)     \-              95 (34.2%)                     90 (10.1%)

  Clinicopathologic N stage ^a^                                                                                 

  N0                                             674 (36.0%)     140 (21.2%)     62 (22.3%)                     237 (26.5%)

  N1                                             432 (23.1%)     123 (18.6%)     74 (26.6%)                     331 (37.0%)

  NX                                             559 (29.9%)     387 (58.5%)     47 (16.9%)                     237 (26.5%)

  Unknown/missing                                207 (11.1%)     11 (1.7%)       95 (34.2%)                     90 (10.1%)

  Location synchronous metastases                                                                               

  Liver                                          N/A             N/A             N/A                            350 (39.1%)

  Peritoneal                                     N/A             N/A             N/A                            119 (13.3%)

  Lymph node                                     N/A             N/A             N/A                            46 (5.1%)

  Lung                                           N/A             N/A             N/A                            11 (1.2%)

  Liver + peritoneum                             N/A             N/A             N/A                            92 (10.3%)

  Other                                          N/A             N/A             N/A                            22 (2.5%)

  Multiple, other                                N/A             N/A             N/A                            175 (19.6%)

  Unknown/missing                                N/A             N/A             N/A                            80 (8.9%)

  Pathology confirmation of primary tumor(yes)   1566 (83.7%)    661 (100%)      156 (56.1%)                    732 (81.8%)

  Differentiation grade                                                                                         

  Well                                           N/A             102 (15.4%)     N/A                            N/A

  Moderate                                       N/A             209 (31.6%)     N/A                            N/A

  Poor                                           N/A             157 (23.7%)     N/A                            N/A

  Not determined                                 N/A             193 (29.2%)     N/A                            N/A

  Radicality                                                                                                    

  R0                                             N/A             417 (63.1%)     N/A                            N/A

  R1                                             N/A             130 (19.7%)     N/A                            N/A

  R2                                             N/A             24 (3.6%)       N/A                            N/A

  Unclear                                        N/A             90 (13.6%)      N/A                            N/A
  -----------------------------------------------------------------------------------------------------------------------------

^a^ Clinical P- and N- for unresected patients and pathologic T- and N- stage for resected patients are provided.

cancers-12-00918-t002_Table 2

###### 

Survival of patients with gallbladder cancer according to clinical stage and treatment strategy.

  Group                              N      Five-year Survival   Median OS, Months (95% CI)   Log Rank Test *p* Value
  ---------------------------------- ------ -------------------- ---------------------------- -------------------------
  Total                              1895   13.2%                5.5 (5.0--6.0)               
  Resected non-metastatic            661    34.2%                23.7 (19.6--27.8)            
  Adjuvant chemotherapy              12     37.5%                29.4 (21.4--37.5)            0.521
  No adjuvant chemotherapy           649    34.1%                23.7 (19.4--27.6)            
  T1b/T2 tumor, no radical surgery   106    30.6%                18.3 (13.8--22.7)            \<0.001
  T1b/T2 tumor, radical surgery      274    52.7%                76.7 (43.0--110.3)           
  Non-resected non-metastatic        278    2.9%                 3.6 (3.1--4.1)               
  No palliative chemotherapy         257    3.0%                 3.5 (2.9--4.0)               0.011
  Palliative chemotherapy            21     \-                   7.7 (4.5--10.8               
  Metastatic                         895    1.3%                 2.9 (2.6--3.2)               
  No palliative chemotherapy         690    0.6%                 2.1 (1.9--2.4)               \<0.001
  Palliative chemotherapy            205    3.7%                 7.3 (6.4--8.2)               

cancers-12-00918-t003_Table 3

###### 

Prognostic factors for patients with resected (**A**) and metastatic (**B**) gallbladder cancer.

  ------------------------------------------------------------------------------------- -------------------------------- ---------------------------------- --------- ------------ --------------- ---------
  **A. Prognostic factors for patients with resected gallbladder cancer. N = 661.**                                                                                                                
  **Characteristic**                                                                    **Univariable Cox Regression**   **Multivariable Cox Regression**                                          
  **HR**                                                                                **95% CI**                       ***p* Value**                      **HR**    **95% CI**   ***p* Value**   
  Grade                                                                                                                                                                                            
  Well                                                                                  1                                                                             1                            
  Moderate                                                                              1.41                             1.02--1.95                         0.036     1.17         0.84--1.61      0.354
  Poor                                                                                  2.67                             1.93--3.70                         \<0.001   2.07         1.49--2.86      \<0.001
  Unknown                                                                               1.45                             1.05--1.99                         0.023     1.74         1.26--2.41      0.001
  Sex                                                                                                                                                                                              
  Female                                                                                1                                                                                                          
  Male                                                                                  0.88                             0.71--1.08                         0.214                                  
  Pathological T stage                                                                                                                                                                             
  T1                                                                                    1                                                                             1                            
  T2                                                                                    1.77                             1.35--2.32                         \<0.001   1.58         1.19--2.10      0.001
  T3/T4                                                                                 3.59                             2.69--4.78                         \<0.001   2.61         1.89--3.61      \<0.001
  Tx                                                                                    3.23                             2.01--5.18                         \<0.001   2.16         1.34--3.50      0.002
  Pathological N stage                                                                                                                                                                             
  N0                                                                                    1                                                                             1                            
  N1                                                                                    2.96                             2.13--4.12                         \<0.001   1.95         1.39--2.74      \<0.001
  Nx                                                                                    2.48                             1.86--3.31                         \<0.001   1.86         1.46--2.66      \<0.001
  Radicality                                                                                                                                                                                       
  R0                                                                                    1                                                                             1                            
  R1/R2                                                                                 3.78                             3.03--4.71                         \<0.001   2.69         2.11--3.43      \<0.001
  Unclear                                                                               1.60                             1.20--2.14                         0.001     1.48         1.10--1.98      0.009
  Adjuvant chemotherapy (yes)                                                           0.67                             0.33--1.36                         0.268                                  
  Prior malignancy (yes)                                                                1.22                             0.93--1.61                         0.150                                  
  Increasing age (years)                                                                1.04                             1.03--1.05                         \<0.001   1.04         1.03--1.05      \<0.001
  **B. Prognostic factors for patients with metastatic gallbladder cancer. N = 895.**                                                                                                              
  **Characteristic**                                                                    **Univariable Cox Regression**   **Multivariable Cox Regression**                                          
  **HR**                                                                                **95% CI**                       ***p* Value**                      **HR**    **95% CI**   ***p* Value**   
  Grade                                                                                                                                                                                            
  Well                                                                                  1                                                                                                          
  Moderately                                                                            1.02                             0.61--1.71                         0.931                                  
  Poor                                                                                  1.45                             0.89--2.36                         0.136                                  
  Unknown                                                                               1.85                             1.16--2.97                         0.010                                  
  Sex                                                                                                                                                                                              
  Female                                                                                1                                                                                                          
  Male                                                                                  0.88                             0.71--1.08                         0.214                                  
  Clinical T stage                                                                                                                                                                                 
  T1/T2                                                                                 1                                                                             1                            
  T3/T4                                                                                 2.01                             1.57--2.58                         \<0.001   1.33         1.02--1.73      0.036
  Tx                                                                                    1.82                             1.41--2.35                         \<0.001   1.33         1.02--1.74      0.035
  Unknown                                                                               3.94                             2.88--5.39                         \<0.001   2.22         1.57--3.15      \<0.001
  Clinical N stage                                                                                                                                                                                 
  N0                                                                                    1                                                                             1                            
  N1                                                                                    1.28                             1.07--1.50                         0.006     1.21         1.02--1.44      0.031
  Nx                                                                                    1.50                             1.25--1.80                         \<0.001   1.54         1.28--1.86      \<0.001
  Unknown                                                                               2.70                             2.11--3.47                         \<0.001   \*\*                         
  Supportive therapy (yes)                                                              1.07                             0.90--1.27                         0.443                                  
  Palliative chemotherapy (yes)                                                         0.46                             0.39--0.54                         \<0.001   0.47         0.39--0.55      \<0.001
  Prior malignancy (yes)                                                                0.93                             0.80--1.08                         0.358                                  
  Increasing age (year)                                                                 1.03                             1.03--1.04                         \<0.001   1.02         1.01--1.03      \<0.001
  ------------------------------------------------------------------------------------- -------------------------------- ---------------------------------- --------- ------------ --------------- ---------

\*\* Removed due to collinearity.
